Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Int J Mol Med. 2019 Apr;43(4):1623-1634. doi: 10.3892/ijmm.2019.4081. Epub 2019 Jan 29.
Breast cancer (BC) is the most common cancer in women around the world. microRNAs (miRNAs/miRs) have been proved to be associated with the development and progression of breast cancer. In the present study, to elucidate the effects of dysregulated miR‑135 on cells and underlying mechanisms in BC, in vitro and in vivo experiments were conducted. The biological functions of miR‑135 were studied using MTT, colony formation, wound healing, transwell assays as well as tumorigenicity analysis. Gain‑ and loss‑ of function of miR‑135 studies revealed that ectopic expression of miR‑135 in MDA‑MB‑468 and MCF‑7 cells significantly inhibited cell growth, migration, invasion and EMT, at least in part through inhibiting the activation of the Wnt/β‑catenin pathway. Moreover, this was reversed in cells which were transfected with miR‑135 inhibitors. Taken together, the results of the present study provided evidence that miR‑135 acted as a tumor suppressor in BC, which may represent a novel therapeutic strategy for the diagnosis and prognosis of BC.
乳腺癌(BC)是全世界女性最常见的癌症。microRNAs(miRNAs/miRs)已被证明与乳腺癌的发生和发展有关。在本研究中,通过体外和体内实验,阐明了失调的 miR-135 对 BC 细胞的影响及其潜在机制。使用 MTT、集落形成、划痕愈合、Transwell 测定和致瘤性分析研究了 miR-135 的生物学功能。miR-135 的增益和缺失功能研究表明,在 MDA-MB-468 和 MCF-7 细胞中转染 miR-135 可显著抑制细胞生长、迁移、侵袭和 EMT,至少部分通过抑制 Wnt/β-catenin 通路的激活。此外,用 miR-135 抑制剂转染的细胞中则出现逆转。综上所述,本研究结果提供了证据表明 miR-135 在 BC 中作为一种肿瘤抑制因子发挥作用,这可能代表了 BC 诊断和预后的一种新的治疗策略。